Goldman Sachs has moved Carl Zeiss Meditec into a Sell recommendation, lowering its price target to €23.00 from €27.00 and signaling what it sees as a material disconnect between the company’s market valuation and its operating outlook. The revised target implies roughly 26% downside from current levels, while Goldman’s average upside across its European medtech coverage sits near 22%.
The bank’s analysts note that Carl Zeiss Meditec is trading above its 10-year relative valuation band and is priced materially higher than peer relationships between organic growth and price/earnings multiples would suggest. In the view of Goldman’s team, the prevailing valuation does not adequately reflect deteriorating fundamental drivers for the business, leaving risk skewed to the downside.
A key factor behind the downgrade is an announced move by the Zeiss Group in June to commit up to €200 million to increase its stake in Carl Zeiss Meditec. Goldman Sachs says that the multiple has been supported by buying that may have propped up the stock beyond what the company’s operating prospects would justify. The analysts expect that as this buying support diminishes, the divergence between price and fundamentals will narrow.
Shares have already underperformed, falling about 21% year-to-date. Goldman Sachs cautions, however, that earnings may still have further to fall and that the worsening top-line outlook has not yet been fully reflected in market valuations.
The firm points to several operational pressures weighing on revenue and profitability. These include the impact of IOL VBP 2.0 and slower placements of capital equipment in an environment of increased centralised procurement. Goldman’s analysts say these trends are likely to restrain procedure volumes and utilisation, which in turn depresses sales and margin progression.
In response to the weaker operating picture, Goldman Sachs has cut its adjusted EBITDA forecasts to reflect modest growth in the near term followed by declines: +2% for FY26, -11% for FY27 and -6% for FY28. Organic sales growth is expected to remain weak in FY26 at an estimated -1.0% before improving to 1.2% in FY27, according to the firm.
The bank also highlights intensifying local competition as an additional source of uncertainty for Carl Zeiss Meditec’s revenue trajectory. Goldman Sachs expects FY26 results - due to be released on 10 Dec - may act as the catalyst that forces consensus estimates to be revised lower.
On profitability metrics, Goldman notes that its adjusted EBITA estimate for FY27 - roughly 8% - sits below consensus, although the firm cautions that consensus estimates are unusually dispersed. The analysts have also trimmed the multiple applied to Zeiss to 13x from 14x to reflect their downgraded organic growth outlook.
Goldman Sachs acknowledges that the company’s Profit Up restructuring programme represents a meaningful shift toward proactive cost management. Nonetheless, the firm says the programme’s benefits will rely on effective execution and are likely to phase in over time. The analysts deem it premature for consensus to assume full realisation of those savings, and they argue that consensus models also understate the weaker revenue path Goldman expects.
Reflecting cuts to its organic growth assumptions, Goldman now projects a 3.2% organic top-line CAGR for FY27-29, down from a prior 4.5% forecast. The lowered multiple and reduced earnings estimates underpin the bank’s Sell recommendation and lower price target.
What this means
Goldman Sachs is concluding that Carl Zeiss Meditec’s current valuation exceeds the level supported by its near-term revenue and earnings prospects, increasing the probability of downside for shareholders. The downgrade combines concerns about softening procedure demand, centralised purchasing dynamics, tougher competition and the timing and magnitude of cost-savings from the company’s restructuring plan.